CA2305294A1 - (-)-phenylpropanolamine en tant que medicament sympathomimetique - Google Patents

(-)-phenylpropanolamine en tant que medicament sympathomimetique Download PDF

Info

Publication number
CA2305294A1
CA2305294A1 CA002305294A CA2305294A CA2305294A1 CA 2305294 A1 CA2305294 A1 CA 2305294A1 CA 002305294 A CA002305294 A CA 002305294A CA 2305294 A CA2305294 A CA 2305294A CA 2305294 A1 CA2305294 A1 CA 2305294A1
Authority
CA
Canada
Prior art keywords
phenylpropanolamine
pharmaceutical composition
dose
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002305294A
Other languages
English (en)
Inventor
Thomas Yorio
Patricia Gwirtz
William T. Sherman
Anthony R. Booth
James L. Caffrey
Peter Raven
Michael Forster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CA2305294A1 publication Critical patent/CA2305294A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques qui comprennent de la (-)-phénylpropanolamine et un excipient acceptable sur le plan pharmaceutique, dans lesquelles la (-)-phénylpropanolamine ne contient pratiquement pas de (+)-phénylpropanolamine. Dans une autre réalisation, la présente invention concerne des procédés de suppression de congestions nasale et bronchique et inducteur de dilatation de pupille par administration, à un mammifère, d'une quantité thérapeutiquement efficace de (-)-phénylpropanolamine. La (-)-phénylpropanolamine utilisée dans ces procédés ne contient pratiquement pas de (+)-phénylpropanolamine et ne présente pas les effets secondaires néfastes associés au traitement avec la (+)-phénylpropanolamine.
CA002305294A 1998-03-23 1999-01-28 (-)-phenylpropanolamine en tant que medicament sympathomimetique Abandoned CA2305294A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7895098P 1998-03-23 1998-03-23
US60/078,950 1998-03-23
US9145298P 1998-07-01 1998-07-01
US60/091,452 1998-07-01
PCT/US1999/002023 WO1999048483A2 (fr) 1998-03-23 1999-01-28 (-)-phenylpropanolamine en tant que medicament sympathomimetique

Publications (1)

Publication Number Publication Date
CA2305294A1 true CA2305294A1 (fr) 1999-09-30

Family

ID=26761154

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002305294A Abandoned CA2305294A1 (fr) 1998-03-23 1999-01-28 (-)-phenylpropanolamine en tant que medicament sympathomimetique

Country Status (3)

Country Link
AU (1) AU2486599A (fr)
CA (1) CA2305294A1 (fr)
WO (1) WO1999048483A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4818541A (en) * 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
IL98179A0 (en) * 1990-05-21 1992-06-21 Norwich Eaton Pharma Pharmaceutical compositions containing phenylpropanolamine
AU7576798A (en) * 1997-05-15 1998-12-08 Warner-Lambert Company Sympathomimetic compounds

Also Published As

Publication number Publication date
WO1999048483A3 (fr) 2000-01-06
WO1999048483A2 (fr) 1999-09-30
AU2486599A (en) 1999-10-18
WO1999048483A8 (fr) 2000-03-02

Similar Documents

Publication Publication Date Title
US10188613B2 (en) Exo-S-mecamylamine formulation and use in treatment
EP1634498B1 (fr) Formulation d'exo-S-mecylamine
AU772807B2 (en) (-)-pseudoephedrine as a sympathomimetic drug
US6664424B2 (en) Stereoisomers with high affinity for adrenergic receptors
US7232837B2 (en) Stereoisomers with high affinity for adrenergic receptors
US20080242733A1 (en) (-)-Pseudoephedrine as a sympathomimetic drug
EP1030659B1 (fr) Composition pharmaceutique comprenant de la (+)-EPHEDRINE et un antagoniste du recepteur H1
CA2305294A1 (fr) (-)-phenylpropanolamine en tant que medicament sympathomimetique
AU2004203648B2 (en) (-)-Pseudoephedrine as a sympathomimetic drug
EP1310247A1 (fr) (+)-ephedrine en tant que médicament sympathomimétique
Booth et al. Pseudoephedrine as a sympathomimetic drug
WO1998051292A1 (fr) Composes sympathomimetiques

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead